NEJM Group

Information about NEJM Group products and services. Follow @NEJM, @NEJMCatalyst, @NEJMEvidence, @NEJM_AI, @NEJMres360, @NEJMkplus, and @JWatch.

[NEJM Group @NEJMGroup]

This Twitter account is no longer active. For up-to-date information and articles from NEJM Group, follow @NEJM, @NEJMCatalyst, @JWatch, @Physns1stWatch, @NEJMres360, @nejmkplus, and @NEJMLibHub.

[PhysiciansFirstWatch @Physns1stWatch]

An FDA advisory committee voted on Thursday that the potential benefits of the Pfizer and BioNTech #COVID19 #vaccine outweigh its risks for people ages 16 years and up.

[NEJM Catalyst @nejmcatalyst]

Celebrating our anniversary today! 🎉 One year ago, we launched NEJM Catalyst Innovations in Care Delivery. NEJM Catalyst itself turns five. Please enjoy some virtual cake, on us. 🍰

[NEJM Clinician @NEJMClinician]

#ASH2020: A preliminary study shows that patients on chronic anticoagulant or antiplatelet drugs for other conditions do not fare better than other patients after receiving a diagnosis of #COVID19. Dr. Gwendolyn Ho chats with @NEJMGroup’s Joe Elia. https://t.co/ym6lKgChbz

[NEJM Clinician @NEJMClinician]

.@PaulSaxMD offers some tips for getting through the next few months safely -- and with some joy -- while we await widespread vaccination against #COVID19. https://t.co/Q80FbXiFDw

[PhysiciansFirstWatch @Physns1stWatch]

Pfizer and BioNTech's mRNA #vaccine against #SARSCoV2 seems to start working soon after the first dose. Meanwhile, the AstraZeneca vaccine showed 62% efficacy among people who received two full doses and 90% efficacy among those who received a half-dose followed by a full dose.

[PhysiciansFirstWatch @Physns1stWatch]

A preliminary study in California shows that patients on chronic anticoagulant or antiplatelet drugs for other conditions don't fare any better than other patients after receiving a diagnosis of #COVID19. Dr. Gwendolyn Ho chats with Joe Elia. https://t.co/DkOtnLbt5I #ASH20

[PhysiciansFirstWatch @Physns1stWatch]

#ASH20 news from @NEJMGroup: Joe Elia interviews Dr. Bhavana Bhatnagar. She reports that African-American patients aged <60 with acute myeloid leukemia have lower 3-year survival compared with whites: 32% vs. 41%. https://t.co/ATjeD0QVPo @BhavanaBhatnag4

[NEJM Clinician @NEJMClinician]

#ASH2020 news from @NEJMGroup: Dr. Terry Gernsheimer discusses her team's research on the prophylactic use of tranexamic acid in patients undergoing treatment for hematologic malignancies https://t.co/EMGFfzV5KO

[PhysiciansFirstWatch @Physns1stWatch]

Inhaled corticosteroids can be used as needed to manage symptoms in patients aged 12 years and up with mild or moderate persistent #asthma, according to updated asthma guidelines from the National Asthma Education and Prevention Program.

[NEJM Clinician @NEJMClinician]

Pooled #SARSCoV2 Surveillance Testing at a U.S. University: Benefits and Costs https://t.co/xxKTqYLuZe #COVID19

[PhysiciansFirstWatch @Physns1stWatch]

The CDC has shortened the minimum amount of time people have to quarantine after a potential #COVID19 exposure from 14 days to as few as 7 days as long as the person is symptom free and tests negative.

[NEJM Clinician @NEJMClinician]

Anticholinergic medications increase the risk for #MildCognitiveImpairment in cognitively normal adults: https://t.co/7V4mD9cmbw

[NEJM Catalyst @nejmcatalyst]

What is your organization doing to advance the transformation of health care? Visit our author center and let us know: https://t.co/B1r2ZQEjlu #HealthCareDelivery #HCLDR #HealthCareInnovation

[PhysiciansFirstWatch @Physns1stWatch]

The CDC's advisory committee voted 13-1 on Tuesday in favor of prioritizing both healthcare workers and residents of long-term-care facilities for vaccination against #SARSCoV2 during the initial phase of vaccination. #vaccine #COVID19

[NEJM Clinician @NEJMClinician]

From the Insights on Residency Training blog: @VivekSantMD, who has seen residents collectively judge each new class of interns since his own intern year, muses about the culture shift he sees happening in residency training today. https://t.co/LCEryRBBPE

[NEJM Clinician @NEJMClinician]

.@PaulSaxMD summarizes great ID questions from a recent online course he co-teaches at Harvard Medical School. https://t.co/UKh2BHuZ7K

[NEJM Catalyst @nejmcatalyst]

In response to its outstanding reception, NEJM Catalyst Innovations in Care Delivery is doubling its frequency to 12 issues per year. Learn about the journal and visit our author center: https://t.co/OP4vf8kTj5 #HealthCareDelivery #HCLDR #HealthCareInnovation

[NEJM Clinician @NEJMClinician]

.@PaulSaxMD offers his list of ID-related things to be thankful for (even in 2020) in his HIV and ID Observations blog. https://t.co/6VWiVoAFBX

[PhysiciansFirstWatch @Physns1stWatch]

The FDA has issued emergency use authorizations for two new #COVID19 treatments, including the antibody cocktail President Donald Trump received early in his illness.